-

SetPoint Medical to Present at Piper Sandler 37th Annual Healthcare Conference

Company will also participate in panel discussion focused on pioneering new therapeutic areas

VALENCIA, Calif.--(BUSINESS WIRE)--SetPoint Medical, a commercial-stage medical technology company dedicated to improving care for people living with chronic autoimmune diseases, today announced that company management will present at the Piper Sandler 37th Annual Healthcare Conference, being held December 2–4, 2025, in New York, New York.

Murthy V. Simhambhatla, Ph.D., CEO of SetPoint Medical, is scheduled to present on Wednesday, December 3, 2025, at 4:30 p.m. Eastern Time. The presentation will provide an update following U.S. Food and Drug Administration (FDA) approval of the SetPoint System® for the treatment of adults living with moderate-to-severe rheumatoid arthritis (RA), as well as the company’s plans to expand access to this first-in-class neuroimmune modulation therapy.

Dr. Simhambhatla will also participate in a panel discussion titled “Pioneering New Markets” starting at 1:00 p.m. on the same day. Other panelists include executives from Endogenex and Kandu Health.

Investors interested in scheduling one-on-one meetings with SetPoint Medical management may contact their Piper Sandler representative.

About SetPoint Medical

SetPoint Medical is a commercial-stage medical technology company dedicated to improving care for people living with chronic autoimmune diseases. The company’s FDA-approved SetPoint System is the first neuroimmune modulation therapy available for people living with rheumatoid arthritis (RA), offering a novel, device-based alternative for those who do not respond to or cannot tolerate biologic or targeted drug therapies. SetPoint’s proprietary integrated neurostimulation platform is designed to activate innate anti-inflammatory pathways in the vagus nerve to reduce inflammation and restore immunologic setpoint. With a vision to redefine the care of autoimmune conditions, SetPoint is also planning to evaluate its platform technology for other conditions including multiple sclerosis and Crohn’s disease. Learn more at setpointmedical.com.

Contacts

Emma Yang
Health+Commerce
media@setpointmedical.com

SetPoint Medical


Release Versions

Contacts

Emma Yang
Health+Commerce
media@setpointmedical.com

More News From SetPoint Medical

SetPoint Medical Announces CMS Transitional Pass-Through Payment Approval for the SetPoint System, the Breakthrough Neuroimmune Modulation Platform

VALENCIA, Calif.--(BUSINESS WIRE)--SetPoint Medical, a commercial-stage medical technology company dedicated to improving care for people living with chronic autoimmune diseases, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status for its neuroimmune modulation device, the SetPoint System®. This approval offers incremental payment for procedures involving the use of the SetPoint System in hospital outpatient and...

SetPoint Medical to Present Data at ACR Convergence 2025 Demonstrating Sustained Efficacy and Safety for the SetPoint System to Treat Rheumatoid Arthritis

VALENCIA, Calif.--(BUSINESS WIRE)--SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, today announced it will share four presentations highlighting new data about the SetPoint System at the upcoming American College of Rheumatology (ACR) Convergence 2025, the largest global gathering of rheumatologists. Presentations will include clinical data demonstrating that the first-of-its-kind SetPoint System’s neuroimmune modulation therapy...

SetPoint Medical Raises $140 Million in Private Financing and Expands Leadership Team to Support Commercialization of Rheumatoid Arthritis Therapy

VALENCIA, Calif.--(BUSINESS WIRE)--SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, announced that it has raised $140 million in private financing, that includes $25 million in the second tranche of its Series C financing, as well as $115 million in its Series D financing, co-led by Elevage Medical Technologies and Ally Bridge Group. Proceeds of the financing will support commercialization of the SetPoint System, a first-of-its-ki...
Back to Newsroom